Matthew Duncan Selby

USPTO Granted Patents = 17 (Patent Applications = 3)

CIPO Patents = 8 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 8.6

ph-index = 4

Forward Citations = 62(Granted Patents)

Location History:

Sandwich, GB (2005 - 2011)
Slough, GB (2016 - 2024)
Berkshire, GB (2024)

Company Filing History:

Agouron Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12391688 - Imidazopyridine derivatives as IL-17 modulators (2025-08-19),

2. 12018021 - Thiophene derivatives for the treatment of disorders caused by IgE (2024-06-25),

3. 11912721 - Fused pentacyclic imidazole derivatives (2024-02-27),

4. 11052076 - Spirocyclic indolines as IL-17 modulators (2021-07-06),

5. 10906919 - Fused pentacyclic imidazole derivatives (2021-02-02),

6. 10202405 - Fused pentacyclic imidazole derivatives (2019-02-12),

7. 10004737 - Fused imidazole and pyrazole derivatives as modulators of TNF activity (2018-06-26),

8. 9932343 - Fused tricyclic benzimidazoles derivatives as modulators of TNF activity (2018-04-03),

9. 9868749 - Fused imidazole and pyrazole derivatives as modulators of TNF activity (2018-01-16),

10. 9550737 - TNF -α modulating benzimidazoles (2017-01-24),

11. 9475820 - Substituted imidazo[1,2-a]pyrazines as TNF activity modulators (2016-10-25),

12. 9309243 - Imidazopyridine derivatives as modulators of TNF activity (2016-04-12),

13. 8063044 - Pyrazole derivatives (2011-11-22),

14. 7435728 - Pyrazole derivatives (2008-10-14),

15. 7157468 - Pyrazole derivatives (2007-01-02),

Title: Innovations and Contributions of Matthew Duncan Selby

Introduction

Matthew Duncan Selby, based in Slough, GB, is a prominent inventor known for his significant contributions to the pharmaceutical field. With a total of 11 patents to his name, Selby's work focuses primarily on the development of novel compounds for the treatment of various medical disorders.

Latest Patents

Two of Selby's latest patents highlight his innovative approach to pharmaceutical solutions. The first patent involves thiophene derivatives designed for the treatment of disorders caused by IgE, which includes allergies and type 1 hypersensitivity. These compounds are expected to provide therapeutic benefits for individuals suffering from conditions linked to IgE.

The second patent centers around fused pentacyclic imidazole derivatives. This series of compounds acts as potent modulators of human TNFa activity, making them valuable in the treatment and prevention of diverse human ailments. These include autoimmune and inflammatory disorders, neurological and neurodegenerative diseases, pain management, cardiovascular issues, metabolic disorders, ocular conditions, and certain types of cancers. Specifically, this patent discusses the innovative 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and their analogs.

Career Highlights

Throughout his career, Matthew Duncan Selby has been associated with several influential companies, including UCB Biopharma Sprl and UCB Biopharma Srl. His work in these organizations has played a pivotal role in advancing pharmaceutical research and development, particularly in drug formulation and therapeutic applications.

Collaborations

Collaboration has been a key element of Selby's innovation process. He has worked alongside esteemed colleagues, such as Zhaoning Zhu and Daniel Christopher Brookings. Their combined expertise has facilitated the exploration and realization of groundbreaking ideas within the pharmaceutical landscape.

Conclusion

Matthew Duncan Selby's contributions to the field of pharmaceuticals through his patents represent a significant advancement in the treatment of various medical conditions. His extensive research and collaborative efforts underscore the importance of innovation within the medical industry, paving the way for future breakthroughs that can enhance patient care and outcomes.

This text is generated by artificial intelligence and may not be accurate.